Compare Organon & Co. Common Stock (OGN) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.25 (market cap $297.21M). The key difference: Organon & Co. Common Stock is far larger — about 12.2× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| OGN | YMAG | |
|---|---|---|
Market Cap | $3.62B | $297.21M |
Volume | 2,892,999 | 809,569 |
Sector | Health | Income / Options Overlay |
52-Week High | $13.81 | $15.68 |
52-Week Low | $5.70 | $10.76 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
YMAG trades at $11.55, up 0.7% today, with a neutral technical signal and bullish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. RSI levels show mixed signals with short-term overbought conditions. Support and resistance levels are tightly clustered around $11-$12, indicating potential for near-term consolidation.
The outlook remains balanced with high distribution yields providing income appeal, though technical indicators suggest limited near-term momentum. Key risks include NAV stability during earnings periods and dependency on underlying option strategies. Analyst coverage is limited, requiring careful monitoring of component fund performance and distribution sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
